Genomic Valley Biotech Ltd
Genomic Valley Biotech Ltd (GVBL) last traded at ₹31.8, a market capitalisation of ₹9.71 crore, on a P/E of 972. Over the past 52 weeks the stock has ranged between ₹20.1 and ₹46.5. Genomic Valley Biotech Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0.04 crore and net profit of ₹0.01 crore. Figures are as of 25 Aug 2026 and are not real time.
Genomic Valley Biotech Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Genomic Valley Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.04 cr, down 55.6% from ₹0.09 cr a year earlier. Net profit was ₹0.01 cr, down 50.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.22 | 0.26 | 0.09 | 0.09 | 0.05 | 0.04 | 0.04 |
| Expenses | 0.07 | 0.06 | 0.26 | 0.06 | 0.09 | 0.04 | 0.04 | 0.02 |
| Operating profit | 0.14 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| OPM % | 66.67% | 72.73% | 0.00% | 33.33% | 0.00% | 20.00% | 0.00% | 50.00% |
| Other income | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.15 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| Tax % | 0.00% | 0.00% | — | 0.00% | — | 0.00% | — | 0.00% |
| Net profit | 0.15 | 0.16 | -0.08 | 0.02 | 0 | 0.01 | -0.01 | 0.01 |
| EPS (₹) | 0.49 | 0.52 | -0.26 | 0.07 | 0.00 | 0.03 | -0.03 | 0.03 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Genomic Valley Biotech Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 | 0.22 |
| Operating profit | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.04 | 0.03 |
| OPM % | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 14.81% | 13.64% |
| Net profit | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 | 0.01 |
| EPS (₹) | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.10 | 0.03 |
TTM is the trailing twelve months to the most recent quarter.
Genomic Valley Biotech Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 5%
- 3 Years
- -54%
- TTM
- -72%
- 10 Years
- 8%
- 5 Years
- 15%
- 3 Years
- -68%
- TTM
- -96%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 11%
- 1 Year
- -28%
- 10 Years
- 2%
- 5 Years
- 5%
- 3 Years
- 4%
- Last Year
- 1%
Genomic Valley Biotech Ltd shareholding pattern
Promoters held 46.06% at Jun 2026, down from 46.72% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.67% | 46.83% | 46.78% | 46.72% | 46.72% | 46.06% | 46.06% | 46.06% |
| Public | 45.33% | 53.16% | 53.20% | 53.28% | 53.29% | 53.94% | 53.94% | 53.94% |
| No. of shareholders | 2,128 | 2,497 | 2,504 | 2,460 | 2,459 | 2,522 | 2,481 | 2,448 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Genomic Valley Biotech Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Genomic Valley Biotech Limited has published its standalone unaudited financial results…
Read the full analysis - Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026.Board Meetinglow impact
Cruxal's analysis: Genomic Valley Biotech Limited has released its standalone unaudited financial results…
Read the full analysis - Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve unaudited financial ....Board Meetinglow impact
Cruxal's analysis: Genomic Valley Biotech Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Genomic Valley Biotech Ltd
Cruxal reads every Genomic Valley Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.